JP2014517008A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517008A5
JP2014517008A5 JP2014514596A JP2014514596A JP2014517008A5 JP 2014517008 A5 JP2014517008 A5 JP 2014517008A5 JP 2014514596 A JP2014514596 A JP 2014514596A JP 2014514596 A JP2014514596 A JP 2014514596A JP 2014517008 A5 JP2014517008 A5 JP 2014517008A5
Authority
JP
Japan
Prior art keywords
use according
medicament
manufacture
muscle
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014514596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517008A (ja
JP6001060B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041119 external-priority patent/WO2012170546A1/en
Publication of JP2014517008A publication Critical patent/JP2014517008A/ja
Publication of JP2014517008A5 publication Critical patent/JP2014517008A5/ja
Application granted granted Critical
Publication of JP6001060B2 publication Critical patent/JP6001060B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014514596A 2011-06-06 2012-06-06 筋萎縮を阻害するための方法 Active JP6001060B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161493969P 2011-06-06 2011-06-06
US61/493,969 2011-06-06
PCT/US2012/041119 WO2012170546A1 (en) 2011-06-06 2012-06-06 Methods of inhibiting muscle atrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016169533A Division JP6175172B2 (ja) 2011-06-06 2016-08-31 筋萎縮を阻害するための方法

Publications (3)

Publication Number Publication Date
JP2014517008A JP2014517008A (ja) 2014-07-17
JP2014517008A5 true JP2014517008A5 (cg-RX-API-DMAC7.html) 2015-07-30
JP6001060B2 JP6001060B2 (ja) 2016-10-05

Family

ID=47296415

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014514596A Active JP6001060B2 (ja) 2011-06-06 2012-06-06 筋萎縮を阻害するための方法
JP2016169533A Active JP6175172B2 (ja) 2011-06-06 2016-08-31 筋萎縮を阻害するための方法
JP2017133423A Pending JP2017226670A (ja) 2011-06-06 2017-07-07 筋萎縮を阻害するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016169533A Active JP6175172B2 (ja) 2011-06-06 2016-08-31 筋萎縮を阻害するための方法
JP2017133423A Pending JP2017226670A (ja) 2011-06-06 2017-07-07 筋萎縮を阻害するための方法

Country Status (8)

Country Link
US (3) US9295664B2 (cg-RX-API-DMAC7.html)
EP (2) EP2717876B1 (cg-RX-API-DMAC7.html)
JP (3) JP6001060B2 (cg-RX-API-DMAC7.html)
CN (2) CN106822153B (cg-RX-API-DMAC7.html)
AU (2) AU2012268036B2 (cg-RX-API-DMAC7.html)
CA (1) CA2838275C (cg-RX-API-DMAC7.html)
IL (2) IL229802A (cg-RX-API-DMAC7.html)
WO (1) WO2012170546A1 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022772A1 (en) 2012-08-03 2014-02-06 University Of Iowa Research Foundation Tomatidine, analogs thereof, compositions comprising same, and uses for same
US11090313B2 (en) * 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
EP2717876B1 (en) 2011-06-06 2018-12-19 University of Iowa Research Foundation Substances and compostions for use in methods of inhibiting muscle atrophy
DK2970205T3 (da) 2013-03-14 2019-07-29 Tolero Pharmaceuticals Inc JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
WO2015095449A1 (en) * 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
CN105884852B (zh) * 2015-01-07 2019-07-05 中国药科大学 齐墩果酸与胆碱的共晶、其制备方法及其药物组合物
NL2015032B1 (en) 2015-06-26 2017-01-24 Vitalnext B V Compositions and methods for the treatment of malnutrition.
JP6791977B2 (ja) 2015-10-29 2020-11-25 エミオン インコーポレイテッドＥｍｍｙｏｎ， Ｉｎｃ． 骨格筋の肥大剤としてのフロスタン−３オール誘導体
CN107058557A (zh) * 2017-05-12 2017-08-18 安徽省农业科学院畜牧兽医研究所 影响猪肉质性状的功能候选基因及其筛选方法
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
WO2019055280A1 (en) * 2017-09-13 2019-03-21 Emmyon, Inc. DIETHANOLAMINE SALTS AND URSOLIC ACID MORPHOLIN
BR112020026947B1 (pt) 2018-07-10 2022-11-22 Novartis Ag Derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, e composição farmacêutica
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
MX2021005906A (es) * 2018-11-20 2021-09-14 Nutreco Ip Assets Bv Composiciones para alimentar a un animal pre?ado.
US10343997B1 (en) 2018-12-04 2019-07-09 King Saud University Ursolic acid derivatives
CN109632773B (zh) * 2019-01-08 2021-11-12 贵州大学 一种二氢硫辛酸琥珀酰转移酶抑制剂的筛选方法
WO2020152367A1 (en) * 2019-01-25 2020-07-30 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
CN111948401B (zh) * 2019-06-26 2022-04-15 浙江大学 CHCHD10在促进AChR亚基基因表达和维持NMJ稳定中的应用
BR112022002769A2 (pt) * 2019-08-16 2022-05-10 Siegfried Labeit Composto, composição farmacêutica, e, método para tratar ou prevenir uma condição
BR112022007867A2 (pt) * 2019-10-30 2022-07-12 Dana Farber Cancer Inst Inc Degradadores de pequena molécula de helios e métodos de uso
WO2021099503A1 (en) * 2019-11-19 2021-05-27 Nutreco Ip Assets B.V. Animal feed and methods for improving animal performance and productivity
JP7648129B2 (ja) * 2020-09-24 2025-03-18 国立大学法人金沢大学 うつ症状の予防、治療及び／又は緩和用組成物並びに運動量増加組成物
KR102802853B1 (ko) * 2021-02-26 2025-05-07 이엑스헬스케어 주식회사 피부 유래 엑소좀을 통해 근손실 억제 또는 근생성 촉진 효과를 나타내는 조성물
CN114622020B (zh) * 2022-03-30 2022-09-27 华南农业大学 一种与鸡生长性状相关的klhl31基因分子标记及应用
US20250368651A1 (en) * 2022-06-27 2025-12-04 University Of Kansas Antiviral compounds useful against sars-cov-2
KR20240078995A (ko) * 2022-11-28 2024-06-04 재단법인 아산사회복지재단 근감소증 진단용 바이오마커 및 이를 이용한 근감소증 진단방법
WO2024243339A2 (en) * 2023-05-23 2024-11-28 Burrell Justin Boldine to reduce muscle atrophy and promote neuromuscular recovery

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2684365A (en) * 1952-02-07 1954-07-20 Mosettig Erich Method of converting tomatidine into delta16-allopregnenolone
US2770618A (en) * 1952-10-07 1956-11-13 American Home Prod Tomatidine derivatives
US2910470A (en) 1958-11-20 1959-10-27 Searle & Co 3-oxocona-1, 4-dienine and intermediates for its preparation
NL124636C (cg-RX-API-DMAC7.html) 1965-02-26
NL6509936A (cg-RX-API-DMAC7.html) 1965-07-30 1967-01-31
US3625941A (en) 1968-04-30 1971-12-07 Searle & Co ALPHA-(2-LOWER ALKYL-2-{8 2-(6-LKOXY OR TERTIARY AMINO-1,2,3,4-TETRAHYDRONAPHTH-1-YLIDEN) ethyl{9 -3-OXO CYCLO-PERET-1-YLIDENAMINOXY OR OXO HYDROZINO) ALKONIC ACID AND ASYMMETRIC FORCES FOR THEIR PRODUCTION
GB1414047A (en) 1973-03-15 1975-11-12 Biorex Laboratories Ltd Ursolic acid derivatives
NZ193564A (en) * 1979-05-02 1985-01-31 Aruba Pty Ltd Steroid alkaloids from solanum sodomeum and pharmaceutical compositions
AU578068B2 (en) 1984-03-08 1988-10-13 Nippon Zoki Pharmaceutical Co., Ltd. Hydantoin derivatives and pharmaceutical compositions containing them
AT396589B (de) 1990-06-05 1993-10-25 Chemie Linz Gmbh Verfahren zur herstellung von allantoin
US5422350A (en) 1992-09-10 1995-06-06 Warner-Lambert Company Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
BE1008235A5 (nl) 1994-03-25 1996-02-20 Univ Gent Analysemethode geschikt om beta-agonisten en beta-antagonisten op te sporen.
AU2753095A (en) 1994-06-24 1996-01-19 Nippon Shinyaku Co. Ltd. Triterpene derivative and medicinal composition
JP3041232B2 (ja) 1995-11-16 2000-05-15 日本ケミカルリサーチ株式会社 癌転移抑制剤
JP3069686B2 (ja) 1997-12-08 2000-07-24 農林水産省四国農業試験場長 フラバノン類含有組成物
AU768130B2 (en) * 1998-04-09 2003-12-04 Johns Hopkins University School Of Medicine, The Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
KR20000019716A (ko) * 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
AUPP968699A0 (en) * 1999-04-09 1999-05-06 Cura Nominees Pty Ltd Therapeutic compositions and method for their preparation
IL133809A0 (en) * 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
WO2002009719A1 (en) 2000-07-31 2002-02-07 The Nisshin Oillio, Ltd. Antitumor agents
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
CA2425356C (en) * 2000-10-13 2015-10-06 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
CA2430346A1 (en) 2000-11-30 2002-06-06 The Nisshin Oillio, Ltd. Beautifying foods and drinks and peroral beautifying preparations
JP3716975B2 (ja) 2001-10-30 2005-11-16 独立行政法人科学技術振興機構 新規ナリンゲニン誘導体及びその用途
EP2289503B1 (en) 2001-12-06 2016-06-29 University of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US20030198684A1 (en) * 2002-04-23 2003-10-23 A. Braswell Composition and method for increasing testosterone levels
US20050090453A1 (en) * 2003-01-15 2005-04-28 Solbec Pharmaceuticals Co., Ltd. Methods of modulating IL-6
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
CN100506092C (zh) 2004-06-08 2009-07-01 千南成 中药解酒饮料
EP1618881A1 (en) * 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
US7772195B2 (en) 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
US7612045B2 (en) 2004-09-14 2009-11-03 Sequoia Sciences, Inc. Compounds, compositions and methods for controlling biofilms and bacterial infections
US20060062863A1 (en) * 2004-09-22 2006-03-23 Shibnath Ghosal Compositions for anti-obesity, health-restorative and health-promotional benefits
US20060083793A1 (en) * 2004-09-29 2006-04-20 Gardiner Paul T Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker
AU2005330504B2 (en) * 2004-09-29 2010-10-28 Harbor Biosciences, Inc. Steroid analogs and characterization and treatment methods
US8143425B2 (en) * 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
KR101254938B1 (ko) 2005-06-10 2013-04-16 포라가세이고오교오가부시끼가이샤 신규 트리테르펜산 유도체 및 이를 포함하는 피부 외용제
WO2007011674A2 (en) 2005-07-15 2007-01-25 Baker Donald J Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals
WO2007053915A2 (en) 2005-11-09 2007-05-18 Universiteit Gent Naringenin derivatives with selectivity on ers
US20090042857A1 (en) 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
US20090203661A1 (en) 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
WO2008058269A2 (en) 2006-11-09 2008-05-15 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
EP2146724A2 (en) 2007-03-16 2010-01-27 The Regent of the University of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy
WO2008156654A2 (en) 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders
US20090163580A1 (en) * 2007-12-24 2009-06-25 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
JP2009209099A (ja) * 2008-03-05 2009-09-17 Kumamoto Univ 動脈硬化の予防・治療剤
US20100040568A1 (en) 2008-04-30 2010-02-18 Skinmedica, Inc. Steroidal compounds as melanogenesis modifiers and uses thereof
JP2010095459A (ja) 2008-10-15 2010-04-30 Kinki Univ 脂肪蓄積・代謝改善剤、抗ＴＮＦ−α作用剤、及び新規トリテルペン化合物
US20100104669A1 (en) 2008-10-28 2010-04-29 Scheffler Armin Method for preparing an aqueous solution containing triterpenic acid, aqueous solution containing triterpenic acid, and use thereof
US20120010176A1 (en) * 2008-11-12 2012-01-12 Khurana Tejvir S Utrophin promoter activity upregulation for the treatment of muscular dystrophy
US20100204121A1 (en) 2009-02-10 2010-08-12 Romero Augustin T Dietary supplements containing terpenoid acids of maslinic acid or oleanolic acid and process for enhancing muscle mass in mammals
EP2246050A1 (en) 2009-04-27 2010-11-03 IMR - International Medical Research - Partner GmbH Combination therapy comprising mechanical vibration for the treatment of a disease of the musculoskeletal or nervous system
WO2010132776A1 (en) 2009-05-14 2010-11-18 Rutgers, The State University Of New Jersey Oregano and mint anti-inflammatory compositions and methods
ES2688447T3 (es) * 2009-10-09 2018-11-02 Nestec S.A. Métodos para prevenir o tratar la sarcopenia y la atrofia muscular en animales
US20110097427A1 (en) * 2009-10-27 2011-04-28 Shyam Ramakrishnan Molecular Targets and Dietary Modulators of Exercise-Induced Muscle Damage
WO2014022772A1 (en) 2012-08-03 2014-02-06 University Of Iowa Research Foundation Tomatidine, analogs thereof, compositions comprising same, and uses for same
JP5808797B2 (ja) 2010-05-20 2015-11-10 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 筋萎縮を阻害するための方法
CA2801487C (en) 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
CN101940616B (zh) * 2010-08-31 2012-07-25 中国药科大学 一种防治糖尿病的风轮菜有效部位的制备方法与药物用途
RS20100392A3 (en) 2010-09-06 2012-12-31 Pavlov, Aleksandar Procedure for obtaining herbal preparation based on herbal mixture extract for application on skin and herbal preparation obtained thereof
WO2012094636A2 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP2717876B1 (en) 2011-06-06 2018-12-19 University of Iowa Research Foundation Substances and compostions for use in methods of inhibiting muscle atrophy

Similar Documents

Publication Publication Date Title
JP2014517008A5 (cg-RX-API-DMAC7.html)
JP2017514910A5 (cg-RX-API-DMAC7.html)
JP2011518833A5 (cg-RX-API-DMAC7.html)
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
JP2012111953A5 (cg-RX-API-DMAC7.html)
JP2011037901A5 (cg-RX-API-DMAC7.html)
JP2013525444A5 (cg-RX-API-DMAC7.html)
WO2011056985A3 (en) Substituted heterocyclic compounds
EA201200794A1 (ru) Триазолопиридины
MX2009009492A (es) Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
TN2010000255A1 (en) Organic compounds
JP2012092103A5 (cg-RX-API-DMAC7.html)
JP2012006970A5 (cg-RX-API-DMAC7.html)
JP2013515006A5 (cg-RX-API-DMAC7.html)
MY189770A (en) Biaryl derivative as gpr120 agonists
EA201301181A1 (ru) Триазолопиридины
EP4327886A3 (en) Pyrimido- pyridazinone compounds and use thereof
JP2015508092A5 (cg-RX-API-DMAC7.html)
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
MX378007B (es) Derivados de biarilo como agonistas de gpr120.
CY1122551T1 (el) Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων
JP2011046708A5 (cg-RX-API-DMAC7.html)
JP2013544892A5 (cg-RX-API-DMAC7.html)
JP2012525422A5 (cg-RX-API-DMAC7.html)